SIM
CRVS icon

Spark Investment Management’s Corvus Pharmaceuticals CRVS Stock Holding History

Spark Investment Management’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-24,500
Closed -$210K – 691
2018
Q3 		$210K Buy
24,500
+8,900
+57% +$89K 0.01% 559
2018
Q2 		$171K Buy
15,600
+4,800
+44% +$53.6K 0.01% 573
2018
Q1 		$124K Sell
10,800
-17,700
-62% -$167K 0.01% 540
2017
Q4 		$295K Buy
+28,500
New +$365K 0.02% 522

Other funds holding CRVS

OrbiMed
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BVF Inc
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
CI
Cowen Inc New York $1.39B AUM 60.14% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Spark Investment Management's CRVS Position: Q4 2018 in Review

Spark Investment Management sold out of Corvus Pharmaceuticals (CRVS) in Q4 2018, closing a stake of 24,500 shares — an estimated $210K sold.

Spark Investment Management first reported a position in CRVS in Q4 2017 and held it in 4 quarters. The position peaked at $295K in Q4 2017. 61 funds tracked by Wall St. Rank hold CRVS as of Q4 2018.

  • Spark Investment Management reported no remaining Corvus Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Spark Investment Management sold 24,500 Corvus Pharmaceuticals shares in Q4 2018, an estimated $210K.
  • Spark Investment Management first reported a position in Corvus Pharmaceuticals in Q4 2017 and held it in 4 quarters.
  • Spark Investment Management's Corvus Pharmaceuticals position peaked at $295K in Q4 2017.
  • 61 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q4 2018.

Based on Spark Investment Management's 13F filing for Q4 2018, filed 12 Feb 2019.